Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritlecitinib in Adult and Adolescent Participants With Alopecia Areata
NCT06873945Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Apr 2025
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of ritlecitinib tosilate in alopecia areata (3 arms), sponsored by Pfizer. Primary endpoints: Percentage of participants with absolute Severity of Alopecia Tool (SALT) score less than or equal to 20 at Week 48, Percentage of participants with TEAEs, SAEs, and AEs leading to discontinuation at Week 52 and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT06873945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06873945.